Have you been diagnosed with primary IgA Nephropathy?

The nefIgArd clinical research study is for patients diagnosed with primary IgA Nephropathy, IgAN, who are at risk of developing end-stage kidney disease even though they are taking medication to preserve kidney function. IgAN, also known as Berger’s disease, is a kidney disease where the antibody called immunoglobulin A, IgA, embeds itself into the kidneys. This causes inflammation, which can affect the kidney’s ability to filter the blood. Some cases of IgAN progress slowly without symptoms or go into remission, while others lead to end-stage kidney failure. Currently, there are no drugs approved specifically to treat IgAN. The purpose of the nefIgArd study is to look at the safety, tolerability, and effectiveness of the study drug Nefecon compared to placebo in patients with IgAN, who are at risk of progressing to end-stage kidney disease To learn more about study participation, contact: Ciara Mitchell at 205-975-9491.